On the epigenomic side, several studies have reported DNA methylation changes in melanoma associated with inactivation of candidate tumor suppressor genes (e.g., MAPK13) or abnormal re-expression of oncogenes during tumor progression (e.g., TBC1D16), when examining pre-selected promoter regions for the presence of DNA methylation, or by genome-wide based approaches [15–23]. Here, TBC1D16 is linked to neoplasm.